{"id":"high-dose-atorvastatin-enoxaparin","safety":{"commonSideEffects":[{"rate":"2-5","effect":"Myalgia or muscle pain"},{"rate":"1-3","effect":"Elevated liver enzymes"},{"rate":"5-10","effect":"Bleeding or bruising"},{"rate":"5-15","effect":"Injection site reactions"},{"rate":"2-4","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1201476","moleculeType":"Oligosaccharide"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atorvastatin (a statin) competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby lowering LDL cholesterol and reducing atherosclerotic plaque formation. Enoxaparin is a low-molecular-weight heparin that potentiates antithrombin III, inactivating factors IIa and Xa to prevent thrombosis. Together, they address both lipid management and acute anticoagulation in cardiovascular disease.","oneSentence":"This combination reduces cholesterol synthesis via statin activity while simultaneously inhibiting thrombin and factor Xa to prevent blood clot formation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:47:38.671Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome with hyperlipidemia"},{"name":"Secondary prevention of cardiovascular events in high-risk patients"}]},"trialDetails":[{"nctId":"NCT05925140","phase":"PHASE1","title":"LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Lebanese University","startDate":"2020-03-28","conditions":"COVID-19, Hospitalized COVID-19 Patients","enrollment":1000},{"nctId":"NCT01063426","phase":"PHASE4","title":"Re-STOP DVT: Reload of High Dose Atorvastatin for Preventing Deep Vein Thrombosis in Statin Users","status":"UNKNOWN","sponsor":"Hallym University Medical Center","startDate":"2009-11","conditions":"Thrombosis, Prevention, Surgery","enrollment":180}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"High dose Atorvastatin+enoxaparin","genericName":"High dose Atorvastatin+enoxaparin","companyName":"Hallym University Medical Center","companyId":"hallym-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination reduces cholesterol synthesis via statin activity while simultaneously inhibiting thrombin and factor Xa to prevent blood clot formation. Used for Acute coronary syndrome with hyperlipidemia, Secondary prevention of cardiovascular events in high-risk patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}